<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628077</url>
  </required_header>
  <id_info>
    <org_study_id>yifeng</org_study_id>
    <nct_id>NCT05628077</nct_id>
  </id_info>
  <brief_title>Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors</brief_title>
  <official_title>Doctor of Medical Sciences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy&#xD;
      in breast cancer patients through telephone follow-up, and analyzed risk factors through&#xD;
      artificial intelligence&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2022</start_date>
  <completion_date type="Anticipated">April 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and risk factors for pain and related adverse reactions among breast cancer survivors on aromatase inhibitors</measure>
    <time_frame>2022-10 ---2023-03</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Aromatase Inhibitors</condition>
  <condition>Endocrine Therapy</condition>
  <condition>Pain</condition>
  <condition>Anxiety</condition>
  <condition>Depression</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>PAIN</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>NO PAIN</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>NO PAIN</arm_group_label>
    <arm_group_label>PAIN</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        I-III Breast cancer survivors on aromatase inhibitors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Breast cancer survivors on aromatase inhibitors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University People'S Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>000000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huifang Li</last_name>
      <phone>18538078485</phone>
      <email>lihuifang19910318@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>March 5, 2023</last_update_submitted>
  <last_update_submitted_qc>March 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yi Feng, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

